Futura Medical plc Board Appointment
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
MinervaX provides clinical and leadership update
- Completed enrolment of 150 pregnant women in a Phase 2 study…
HEALTHCAP STRENGTHENS SENIOR TEAM
Mårten Steen Promoted to Co-Managing Partner
Expanded team…
Arix today announces the following updates to its Board and Executive team
LONDON, 6 October 2021: Arix Bioscience plc (“Arix” or the…
Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer
Industry veteran with decades of experience in company formation,…
Amber Implants VCFix® spinal system receives US FDA Breakthrough Designation
The Hague, Netherlands, 5 October 2021: Amber Implants, an innovative…
DelSiTech Awarded UnitaidExplore Funding for Innovations in Paediatric Healthcare
DelSiTech Awarded UnitaidExplore Funding for Innovations in Paediatric…
ExeVir Bio BV announces its participation in the 8th Annual Healthtech Investment Forum organized by SACHS Associates taking place virtually 5th-6th October 2021.
Torsten Mummenbrauer, Chief Executive Officer of ExeVir will…
Versameb at Sachs 21st Annual Biotech in Europe Forum
Isabel Ferreira speaking on the “Platform Technologies and…
Optimum Strategic Communications Hosts 13th Annual Healthcare Investor Conference
- World Class Speakers from Biotech & Healthcare Industry…
Arix Bioscience plc Interim results for the six months ended 30 June 2021
LONDON, 12 August 2021: Arix Bioscience plc (“Arix”, LSE:…
Optimum Strategic Communications Expands Team to support ongoing growth
Optimum is pleased to announce the appointment of Stella Lempidaki.
With…
Novo Holdings posts record income and returns of DKK 29 billion (EUR 4 billion) in 2020
Novo Holdings’ 2020 result is based on a strong performance…
Niall Kirk, Friend and Founder of Optimum Strategic Communications
It is with great sadness that we have to inform you that our…
Optimum Strategic Communications 12th Annual Healthcare Investor Conference
- Future of healthcare conference in partnership with Dechert…
Optimum recognised for its work in the M&A PR advisor league tables
The Optimum team is very proud to be recognised for our work…
Optimum European Healthcare Investor Survey
European investors continue actively investing in healthcare. The survey held in May 2020 includes responses from 24 of the most influential European VCs, investing approximately EUR 15.5 billion in aggregate in the Healthcare sector.
Optimum European Healthcare Investor Survey
Optimum Strategic Communications (Optimum), conducted a survey of European Venture Capital (VC) investors and the impact of COVID-19 on the Healthcare Sector.
Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
LONDON, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York